spacer
home > ebr > winter 2003 > clinical applications of small molecule p38 map kinase inhibitors
PUBLICATIONS
European Biopharmaceutical Review

Clinical Applications of Small Molecule p38 MAP Kinase Inhibitors

Tumour necrosis factor alpha (TNF-a) and interleukin-1 beta (IL-1b) are pro-inflammatory cytokines that play a key role in the communication between cellular components (leukocytes, macrophages, endothelial cells and so on) that drive inflammatory processes underlying a broad range of diseases. Injectable biological therapies specifically targeting the inhibition of TNF-a (infliximab and etanercept) or IL-1 (anakinra) are clinically validated in the treatment of rheumatoid arthritis (RA), psoriatic arthritis, psoriasis and Crohn's disease (CD). TNF inhibitors in particular have become a gold standard of disease-modifying treatment in patients with severe RA.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Leslie Williams, Program Executive for Vertex's p38 MAP Kinase Development Team

Dr Leslie Williams is Program Executive for Vertex's p38 MAP kinase development team and is also Head of Drug Safety and Medical Writing at Vertex. Leslie joined Vertex in 2000 after seven years of clinical experience in medical information and Phase III and IV post-marketing safety surveillance at two major pharmaceutical companies. Leslie holds a Doctorate of Veterinary Medicine and is a Diplomat of the American College of Veterinary Anesthesiology. Prior to joining the pharmaceutical industry, Leslie served as a Faculty Member and Section Head of Anesthesia at Tufts University School of Veterinary Medicine.

spacer
Dr Leslie Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AstroNova introduces its range of grass paper labels derived from grass for high quality organic products

Dietzenbach, 29 April 2019, AstroNova GmbH, European headquarters of AstroNova Inc. (RI, USA), responsible for Sales and Customer Service in Europe, the Middle East and Africa (EMEA), is extending its Product Identification range with new approved labelling for direct foodstuff contact.
More info >>

White Papers

Assessing the Integrity of Pharmaceutical Packaging Using the Sepha Blisterscan and Conventional Blue Dye Leak Testing Methods

Sepha Limited

A new whitepaper by a leading packaging expert from the University of Ulster, Dr Dorian Dixon, into the integrity of pharmaceutical packaging has established that existing methods for testing the seal integrity of blister packs are not as accurate as newer, technology based test equipment.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement